AWM
BCTX

Apollon Wealth Management’s Briacell Therapeutics BCTX Stock Holding History

Apollon Wealth Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-119
Closed -$101K – 861
2022
Q3 		$101K Buy
119
+13
+12% +$13K 0.01% 765
2022
Q2 		$92K Buy
106
+13
+14% +$12.8K 0.01% 719
2022
Q1 		$141K Sell
93
-60
-39% -$71K 0.01% 713
2021
Q4 		$190K Buy
153
+24
+19% +$31.4K 0.01% 714
2021
Q3 		$157K Buy
+129
New +$119K 0.02% 446

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Apollon Wealth Management's BCTX Position: Q4 2022 in Review

Apollon Wealth Management sold out of Briacell Therapeutics (BCTX) in Q4 2022, closing a stake of 119 shares — an estimated $101K sold.

Apollon Wealth Management first reported a position in BCTX in Q3 2021 and held it in 5 quarters. The position peaked at $190K in Q4 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2022.

  • Apollon Wealth Management reported no remaining Briacell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 119 Briacell Therapeutics shares in Q4 2022, an estimated $101K.
  • Apollon Wealth Management first reported a position in Briacell Therapeutics in Q3 2021 and held it in 5 quarters.
  • Apollon Wealth Management's Briacell Therapeutics position peaked at $190K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2022.

Based on Apollon Wealth Management's 13F filing for Q4 2022, filed 15 Feb 2023.